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Typical medullary breast carcinoma:  
clinical outcomes and treatment results
Andrzej Stelmach1, Janusz Ryś2, Jerzy W. Mituś1, Anna Patla3, Piotr Skotnicki4,  
Marian Reinfuss3, Elżbieta Pluta3, Tomasz Walasek3, Beata Sas-Korczyńska5
Typical medullary breast carcinoma (T-MBC) accounts for less than 1% of all malignant breast neoplasms, and immu-
nohistochemically is characteristic of “triple-negative” breast carcinoma. The purpose of this study was to describe 
the clinical characteristics and treatment results for patients with T-MBC treated at a single institution, and discuss 
the controversial aspects of this very rare form of breast cancer. Analyses was performed in 120 patients with T-MBC 
who were treated between 1970 and 2005. These cases represent 1.1% of all (11 270) patients treated for breast 
cancer during this period. According to TNM classification, 26 patients (21.6%) were in stage I, 80 patients (66.7%) 
in stage II and 14 (11.7%) in stage III of clinically advanced breast cancer. Involved axillary lymph nodes occurred in 
just 10 (8.3%) of the patients, and in all cases metastases were observed in 1–3 lymph nodes. All the patients un-
derwent primary surgery. Radical mastectomies were performed on 98 (81.6%) patients, while the other 22 (18.4%) 
underwent breast-conserving surgery (BCS). Radiotherapy was performed in 36 patients (22 after BCS and 14 after 
mastectomy). Patients with nodal involvement (10 patients) received adjuvant chemotherapy, and 8 patients with 
hormone receptor expression received hormonotherapy with tamoxifen. The 10-year DFS rate was 90%. Out of 120 
patients with T-MBC, only 4 (3.3%) died from this cancer. We showed that none of the population, neither clinical nor 
microscopic, had a statistically significant influence on the 10-year disease-free survival rate. Our results are similar 
to others presented in literature.
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Introduction
According to the WHO classification, medullary carcino-
ma is a well-circumscribed tumour (with pushing margins), 
composed of poorly differentiated cells with scant stroma 
and prominent lymphoplasmacytic infiltration. The cells of 
classic medullary carcinoma are characterised by abundant 
cytoplasm and pleomorphic high-grade vesicular nuclei. 
They are arranged in syncytial structures which constitute 
8at least 75% of histologically sampled areas. What is more, 
the histological texture of medullary carcinoma lacks tubular 
differentiation [1]. The above-mentioned criteria are similar 
to those presented by Ridolfi et al. in 1977 [2]. Tumours 
displaying all these definitive characteristics are classified 
as (classic) medullary carcinomas. When most, but not all, 
of these necessary histological features are present, the 
latest edition of the WHO classification recommends that 
the tumour be classified as invasive carcinoma NST with 
medullary features. 
According to WHO, medullary breast carcinoma (classic, 
typical) accounts for less than 1% of all malignant breast 
neoplasms, and the higher incidence of this carcinoma re-
ported by many authors is due to the inclusion of NST with 
medullary features among patients with invasive carcino-
ma [1, 3, 4] Typical medullary breast carcinoma (T-MBC) 
occurs more frequently in patients with mutations of the 
suppressor gene BRCA-1 present. The mutation of this gene 
is more frequently observed [1, 5–11] in patients with T-MBC. 
Immunohistochemically T-MBC is usually characterised by 
features typical of basal-like carcinomas; they do not express 
oestrogen, progesterone and HER 2/neu receptors. Hence, 
they were included in so-called “triple-negative” breast car-
cinomas [1, 5–7, 12–21]. 
The purpose of this study was to describe the clinical 
characteristics and treatment results for patients with T-MBC 
treated at a single institution in Poland, and discuss the 
controversial aspects of this very rare form of breast cancer. 
Patients and methods
Between January 1970 and December 2005, 120 women 
with T-MBC were treated at the Maria Skłodowska-Curie 
Memorial Cancer Center and Institute of Oncology in Kra-
ków (MSCCCIO). These cases represent 1.1% of all (11 270) 
patients treated for breast cancer during this period. All the 
histologic slides were re-examined, and a diagnosis of T-MBC 
was made according to WHO criteria [1]. The stage of can-
cer was determined using the recently adopted UICC TNM 
classification for breast cancer at the treatment planning 
stage. All the patients received initial surgical treatment 
at the MSCCCIO, and they underwent all other therapeutic 
procedures, such as postoperative radiotherapy, adjuvant 
chemotherapy and hormonotherapy in the same institution. 
The clinopathological characteristics of patients with 
T-MBC is presented in Table I.
The youngest patient in the study group was 26 years 
old and the oldest was 72: the mean age of the patients was 
51 and the median age was 52. A total of 94 of the patients 
(78.3%) were aged between 35 and 64; 10 (8.3%) of the pa-
tients were aged below 35 and 16 (13.3%) were aged above 
64. On the other hand, 58 patients (48.3%) were younger 
than 51 and 62 (51.7%) were older than 51 years. A total of 
26 patients (21.6%) were diagnosed with stage I clinically 
advanced cancer according to the TNM UICC classification, 
while 80 patients (66.7%) were diagnosed with stage II and 
14 (11.7%) with stage III. An examination of the post-surgical 
material revealed that the breast tumour was less than 2 cm 
in diameter in 45 of the patients (37.5%), ranged between 
2 and 5 cm in 70 patients (58.3%), and was more than 5 cm 
in diameter in 5 patients (4.2%). Microscopy revealed that 
metastases in the axillary lymph nodes occurred in just 
10 (8.3%) of the patients, while in all cases metastases 
were observed in 1–3 lymph nodes. The analysis revealed 
no expression of oestrogen receptors (ER) in 112 patients 
(93.3%), no expression of progesterone receptors (PgR) in 
115 patients (95.8%), and expression absence of HER2/neu 
receptors in 105 (87.5%) patients. The treatment methods 
used for patients with T-MBC are presented in Table II.
All the patients underwent primary surgery. Radical 
mastectomies (Halsted during the period 1970–1982, 
Patey or Madden in 1883–2005) were performed on 98 
(81.6%) patients, while the other 22 (18,4%) patients 
treated between 1995 and 2005 underwent breast-
-conserving surgery (BCS). All those patients who un-
derwent BCS received adjuvant radiotherapy. A dose of 
Table I. The clinicopathological characteristics of patients with T-MBC
Characteristics No. of patients %
Age (years)
< 51 58 48.3
≥ 51 62 51.7
Stage (TNM)
I 26 21.6
II 80 66.7
IIIA 14 11.7
Tumour size (pT)
< 2 cm (pT1) 45 37.5
2–5 cm (pT2) 70 58.3
> 5 cm (pT3) 5 4.2
Lymph node status (pN)
pN0 110 91.7
pN+ (1–3) 10 8.3
pN+ (≥ 4) – –
ER status:
Positive 8 6.7
Negative 112 93.3
PgR status:
Positive 5 4.2
Negative 115 95.8
HER 2/neu status:
Positive 15 12.5
Negative 105 87.5
Total 120 100.0
950 Gy administered in 25 fractions was delivered over 
the course of 5 weeks to the whole breast using the 
two tangential fields technique. This was followed by 
a boost (10 Gy administered in 5 fractions) to the tumour 
bed. After mastectomy procedures, 14 of the 98 patients 
(with pN+, and/or pT > 5 cm) received adjuvant radiothe-
rapy at a dose of 50 Gy in 25 fractions administered to the 
chest wall with scar and regional (axillary, internal mamma-
ry and supraclaviculor) lymphatic areas. Patients with nodal 
involvement received adjuvant chemotherapy according to 
a CMF (cyclophosphamide, methotrexate, and 5- fluoroura-
cil) schedule. Endocrine therapy with tamoxifen was admi-
nistered to 8 (6.7%) patients with PgR and/or ER expression.
Treatment efficacy was measured on the basis of 10-
-year disease-free survival (DFS) rates. The Kaplan-Meier 
estimation was used for this purpose. The long rank test 
was applied to evaluate the significance of the results. The 
statistical significance level was established at p ≤ 0.05. 
Results 
All the patients were followed up for a period of at least 
10 years (or until their deaths). The median follow-up time 
was 14 years. The 10-year DFS rate was 90%. 
The relationship between the results of treatment and 
population, clinical and microscopic characteristics, expres-
sion of the c-erb-B2 gene and the presence of hormone 
receptors are presented in Table III.
As shown in Table III, it was not confirmed in the patient 
study group whether any of the studied population, clinical 
and microscopic factors, or any factors analysed immuno-
histochemically, had a statistically significant influence on 
the 10-year disease-free survival rate. 
The patients’ follow-up and the causes of treatment 
failure are presented in Table IV. 
Three patients died from myocardial infarction, two 
from haemorrhage, one from acute pancreatitis, one from 
lung cancer and one from infiltrating ductal carcinoma 
of the second breast. The other patients died as a result 
of distant T-MBC metastases in the bones, the lungs, the 
brain and the liver. 
Table II. The treatment methods delivered in the presented group of 
patients with T-MBC
Treatment method No. of patients %
Surgery
Mastectomy 98 81.6
Breast-conserving surgery (BCS) 22 18.4
Radiotherapy
Yes 36 30.0
No 84 70.0
Chemotherapy
Yes 10 8.3
No 110 91.7
Hormonal therapy
Yes 8 6.7
No 112 93.3
Total 120 100.0
Table III. Treatment results in 120 patients with T-MBC in relation 
to population, clinical, microscopic and immunohistochemically 
characteristics
Characteristics No of  
patients
10-year disease-free survival
No. of patients %
Age
< 51 58 52 89.7
≥ 51 62 56 90.3
TNM stage
I 26 24 92.3
II 80 72 90.0
IIIA 14 12 85.7
Tumour size (pT)
< 2 cm 45 41 91.1
2–5 cm 70 63 90.0
> 5 cm 5 4 80.0
Node status (pN)
pN0 110 102 92.7
pN+ (1–3) 10 6 60.0
ER status
Positive 8 7 87.5
Negative 112 101 90.2
PgR status
Positive 5 4 80.0
Negative 115 104 90.4
HER 2/neu status
Positive 15 13 86.7
Negative 105 95 90.5
Total 120 108 90.0
Table IV. The follow-up and patterns of treatment failure in 120 patients 
with TMBC
Follow-up and causes of death No. of patients %
10-year DFS 108 90.0
Cause of death:
Distant metastases of T-MBC 4 3.3
Other 8 6.7
Total 120 100.0
DFS — disease-free survival
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To sum up, out of a total of 120 patients with T-MBC 
in the study group, only 4 (3.3%) died from this cancer; 
in all these patients a microscopy revealed metastases in 
the axillary lymph nodes. None of the 110 patients with 
T-MBC without lymph node metastases died of the disease; 
hence all the patients who underwent breast-conserving 
treatment survived for 10 years disease-free. 
Discussion
In this study we presented the clinical characteristics 
and treatment results for patients with T-MBC at the same 
institution and we discussed the controversial problems 
relating to adjuvant systemic treatment of this rare breast 
cancer. 
Clinicopathologic characteristics 
Our analysis proved that in patients with T-MBC:
 — the mean age was 51 years (26–72), median — 52 years;
 — the percentage of patients with stage I–II TNM was al-
most 90%;
 — the percentage of patients with pT ≤ 5 cm and pN0 was 
above 90%;
 — ER and PgR negative status was observed in more than 
90% of the patients;
 — HER-2/neu negative status was observed in almost 90% 
of the patients.
Similar population, microscopic and clinical characteri-
stics, as well as immunohistochemically studied factors can 
be found quite often in the literature, obviously in varying 
frequency and intensity [1, 2, 15, 17, 18, 21–30]. However, it is 
important to stress that making strict comparisons between 
the present study group of patients and groups presented 
by other authors is very difficult and remains a questionable 
approach, since a T-MBC diagnosis itself is problematic and 
controversial. It is important to bear in mind the inconsisten-
cies pointed out in the literature when it comes to assessing 
the type of cancer (T-MBC vs invasive carcinoma NST with 
medullary features) between pathologies (interobserver), 
as well as inconsistencies in assessing the same pathology 
(intraobserver). The WHO itself has stressed the difficulties 
involved in applying in practice strict T-MBC criteria [1]. 
Some authors have discussed an overall group of patients 
with T-MBC, so-called atypical MBC — A-MBC, and even 
with invasive NST carcinoma with medullary features; some 
publications from the 1960s and 1970s are in this respect 
difficult to verify. 
Age of patients
The mean age of patients in the study group was 51 
years; similar values have been reported by Vong et al. [31] 
— 51.7, Wong et al., [29] — 51.0 and Martinez et al. [27] — 
50 years; meanwhile, lower values have been reported by 
Khomsi et al. [23] — 47.5, Vu — Nishino et al. [16] — 47.5, 
Yilmaz et al. [32] — 48.3, Wargotz & Silverberg [24] — 45 
years, Thurman et al. [22] — 44 years, and Vo et al., which 
noted a mean survival of as low as 39.2 years [30]. The vast 
majority of researchers stress that the percentage of cases 
of MBC is higher among young patients with lung cancer 
than it is in older patients [1, 22, 16–18, 28, 33–35]. A study 
conducted by CASH (Cancer and Steroid Hormone Study) 
noted that the higher the age, the lower the percentage of 
patients with MBC; it was highest in the 20–29 and 30–39 
age brackets, while among patients aged 40–49 and 50–54, 
it was still higher than in older patients [33, 34]. In 1995 Berg 
and Hunter observed a high percentage of MBC in young 
patients, highest among patients aged < 30; among patients 
aged 30–34 it was confirmed in 8% of cases, among patients 
aged 45–49 it was present in only 3% of cases, and in the 
75–79 age group — 1.5% [35]. 
Stage of disease
A total of 88.3% of the patients in the study group were 
diagnosed with stage I or II of the disease according to 
the TMN classification. This result is in accordance with the 
observations of many authors who emphasis that patients 
with this advanced stage of the disease clearly predominate 
in percentage terms [2, 10, 18, 21, 22, 24, 25, 28–30]. Accor-
ding to certain authors, patients with stages I and II° of the 
disease represent more than 90% of the total. For example, 
Cao et al. report a figure of 94.6%, Anz et al. — 92.3%, and 
Zhang et al. — 96.2% [18, 28, 36]. 
Size of tumour in the breast
In more than 95% of patients in the study group, the 
breast tumour (pT) did not exceed 5 cm. Bertucci et al. [6] 
and Vo et al. [30] reported exactly the same percentage of 
pT1 and pT2 tumours. Hang et al. reported that tumours 
< 5 cm accounted for 92.3% [28] of the total, while Cao et al. 
gave a figure of 97.4% [18] and Flucke et al. — 98.2% [17]. 
Meanwhile both Wang et al [29] and Vu-Nishino et al. [16] 
reported that such tumours accounted for approximately 
100% of their cases. 
Microscopic state of axillary lymph nodes
Micropscopy revealed the absence of metastases in the 
axillary lymph nodes of 91.7% of the patients in the study 
group; in the remaining 8.3% of cases, metastases were iden-
tified in 1–3 lymph nodes. Patients with T-MBC tend to have 
a lower overall frequency of ALN (axillary lymph node) me-
tastases than patients with invasive ductal carcinoma with 
medullary features or usual invasive ductal carcinoma [2, 
16, 17, 21, 22, 24, 25, 27–29, 31, 37–40]. Martinez et al. 
[27] identified pN0 in 71.7% of patients, Flucke et al. [17] 
— 75%, Vo et al. [30] — 76.7%, Khomsi et al. [9] — 78.8%, 
Thurman et al. — 90% [22] and Zhang et al. [28] — 92.3%. 
When nodal metastases are present, they typically involve 
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no more than three lymph nodes [18, 22, 24, 25, 37, 40–42]. 
Cao et al reported the following observations: 70.2% of 
patients with pN0, 23.9% pN+ (1–3) and 5.9% pN+ (> 3), 
while Thurman et al. noted 90% of patients with pN0 and 
10% with pN+ (1–3) [22]. 
Oestrogen and progesterone receptors  
and c-erb B2 gene expression
The general view is that T-MBC indicates negative pro-
gesterone and oestrogen receptors as well as an absence 
of c-erbB2 gene expression [1, 5, 6, 12, 1, 16–19, 27, 30, 31, 
37, 42–45], while no progesterone receptors were identified 
in 95.8% of cases and c-erb B2 gene expression was only 
noted in 12.5% of cases. Bertucci et al. described a group of 
patients, in 100% of whom there were no oestrogen recep-
tors and in 96% no progesterone receptors [6]. Jacquemier 
et al. presented a study in which they identified negative 
oestrogen receptors in 89.5% of patients and negative pro-
gesterone receptors in 48.7% [5]; Matkovic et al. reported 
percentages of 94.0% and 83%, respectively [44]. In an ana-
lysis of 13 controlled clinical studies, Huober et al. observed 
negative oestrogen and progesterone receptors in 81% of 
patients [26]. The c-erb B2 gene expression was shown to be 
absent in 100% of the patients observed by Bertucci et al. 
[6] and Vang et al. [31], in 94.4% of the patients studied by 
Jacquemier et al. [5] as well as in 93.4% of cases in a study 
conducted by Flucke et al. [17].
Efficacy of treatment for patients with T-MBC
Of the 120 patients with T-MBC comprising the study 
group, a total of 108 (90%) survived disease-free for 10 
years. Only 4 (3.3%) of the patients died as a result of T-MBC, 
all with metastases occurring in the axillary lymph nodes 
91-3N+). None of the 110 patients with T-MBC, in whom 
no metastases occurred in the axillary lymph nodes, died 
of the disease.
Table V shows the treatment results for MBC according 
to the data from the literature. According to Table V and 
other data from the literature, the 10-year survival rate for 
patients with MBC varies between 63% and 94.9%, while 
the 5-year survival rate ranges from 70% to 92.3%; these 
significant differences mainly result from differences in the 
clinical and microscopic composition (T-MBC vs invasive 
carcinoma NST with medullary features) of the groups of 
patients being compared [16, 18, 21, 22, 24–27, 29, 39, 45]. 
The vast majority of the researchers stress that the prognosis 
for patients with MBC is good or even very good, especially 
in the case of T-MBC, and is significantly better than among 
patients with invasive ductal carcinoma [2, 5–7, 11, 13, 14, 
16–18, 21–23, 25–28, 37, 40, 42, 45–48]. Koerner provided an 
analysis of five series, which included a pathologic review of 
cases recorded as medullary carcinoma (MBC) or as invasive 
ductal carcinoma with medullary features [37]; fewer than 
50% of the lesions were accepted as MBC, and the remaining 
cases were diagnosed as invasive ductal carcinomas with 
medullary features or invasive ductal carcinomas [2, 24, 
25, 40, 42]. Patients with MBC proved to have a statistically 
significant more favourable prognosis than those in either 
of the other two groups [37]. 
A study conducted by Cao et al. showed the following 
10-year overall survival rates: 91% for patients with BM and, 
81% for patients with invasive ductal carcinoma. Gjerstorff 
reported results of 84% and 63%, respectively [18, 45]. Me-
anwhile, Martinez et al. observed 14-year survival rates of 
66% and 57%, respectively, including, 80% and 73% for pN0 
patients, respectively and 63% and 49% for pN+ patients, 
respectively [27]. Undoubtedly surprising is the fact that the 
prognosis for T-MBC, despite its “triple negative breast can-
cer” features, is good or even very good, indeed significantly 
better than it is for infiltrate ductal breast carcinoma. Most 
authors think that this is due to the presence of abundant 
lymphoplasmacytic infiltration that is inseparably associated 
with this cancer [49, 50]. Jacquemier et al. as well as Bertucci 
et al. suggest that this may partly be a result of myoepithelial 
differentiation T-MBC [5, 6].
Treatment of T-MBC
The current treatment of choice for patients with T-MBC 
is breast conserving therapy (BCT) supplemented with ra-
diotherapy. This is particularly the case with patients with 
breast tumours not exceeding 3 cm; sentinel lymph node 
mapping is an appropriate procedure for staging axillary 
lymph nodes [37]. It should be stressed that the prognosis 
for patients with small, node-negative T-MBC is particularly 
favourable with a 10-year DFS rate of 90% or better [2, 24]. 
Table V. Treatment results in patients with T-MBC
Author, reference,  
year of publication
Survival rates
10-year 5-year
Rapin V et al. [24] 1988 92.0% –
Reinfuss M et al. [39] 1995 – 78.0%
Thurman SA et al. [21] 2004 63.0%
Vu-Nishino H et al. [16] 2005 94.9% –
Gjerstorff MF et al. [45] 2006 84.0% –
Khomsi F et al. [22] 2007 – 85.0%
Vo T et al. [29] 2007 79.5% 89.0%
Martinez SR et al. [26] 2011 78.0% –
Huober J et al. [25] 2012 66.0% (14-year) –
Zhang J et al. [27] 2013 – 92.3% (6-year)
Cao AY et al. [18] 2013 91.0% –
Stelmach A et al. [present] 2016 90.0% –
12
In the study group, all 22 patients treated with BCT survived 
for 10 years disease-free. 
Adjuvant chemotherapy can probably be omitted in 
patients with T1 N0 M0 TMBC; the indications for systemic 
adjuvant therapy in other patients are similar to those for 
non-medullary invasive duct carcinoma. 
Conclusions
1. The population, microscopic and clinical characteristics 
as well as selected immunohistochemically assessed 
features of T-MBC are:
 — a mean age of 51 years;
 — almost 90% are stage I or II patients;
 — more than 90% patients had breast tumours (pT) 
not exceeding 5 cm;
 — more than 90% of the patients had negative axillary 
lymph nodes;
 — no patients developed metastases in more than 3 
axillary lymph nodes;
 — absence of progesterone and oestrogen receptors 
expression in more than 90% of the patients;
 — absence of c-erb B2 expression was observed in more 
than 90% of the patients.
2. The 10-year disease-free survival rate for the author’s 
own material was 90%. Only 3.3% of the patients (4/120) 
died from T-MBC, all of them from metastases in the 
axillary lymph nodes (N+ 1–3). None of the 110 patients 
with no metastases in the axillary lymph nodes (N0) 
died from T-MBC. 
3. The surgical procedure of choice for patients with 
T-MBC, is, with the right indications, breast conserving 
therapy (BCT). Of the 22 patients who underwent BCT 
from the author’s own material, all survived for 10 years 
disease-free. 
4. T-MBC patients with no metastases in the axillary lymph 
nodes require no adjuvant chemotherapy.
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